





## Catalysis

Initial catalytic tests using **1** as a pre-catalyst and 2-(2-thienyl)pyridine as a substrate focused on the optimisation of the reaction conditions and the assessment of whether a hydrogen acceptor would be required. When norbornene was employed as a hydrogen acceptor, a nearly quantitative yield was obtained after 24 h at 110 °C; however, under acceptor-less conditions only a 45% yield was achieved. Other hydrogen acceptors such as cyclohexene or 3,3-dimethyl-1-butene were tested, although somewhat lower yields were obtained.

In order to assess the scope of **1** as a pre-catalyst for the silylation of C–H bonds with different hydrosilanes, a variety of aromatic substrates with and without a directing group (Schemes 2 and 3, respectively) were examined. The catalytic reactions were performed in THF at 110 °C in a sealed flask using a 5 mol% catalyst loading and a hydrosilane/arene ratio of 3 : 1.

The use of **1** as a pre-catalyst permits the silylation of 2-(2-thienyl)pyridine with a wide range of hydrosilanes, namely, Et<sub>3</sub>SiH, Ph<sub>2</sub>MeSiH, PhMe<sub>2</sub>SiH, Ph<sub>3</sub>SiH and (EtO)<sub>3</sub>SiH. Remarkably, to the best of our knowledge, these are the only examples of the intermolecular catalytic silylation of aryl C–H bonds that successfully employ triaryl-<sup>17</sup> or trialkoxy-silanes (excluding the



Scheme 3 Non-directed dehydrogenative silylation of aromatic and heteroaromatic rings. Reaction conditions: cat **1** (5 mol%), norbornene (0.40 mmol), arene (0.13 mmol), R<sub>3</sub>SiH (0.40 mmol) in THF (2 mL) at 110 °C. Isolated yields are shown. <sup>a</sup> Disilylated product was identified in 7% yield.



Scheme 2 Directed dehydrogenative silylation of aromatic and heteroaromatic rings. Reaction conditions: cat **1** (5 mol%), norbornene (0.40 mmol), arene (0.13 mmol), R<sub>3</sub>SiH (0.40 mmol) in THF (2 mL) at 110 °C. Isolated yields are shown. <sup>a</sup> Yield determined by <sup>1</sup>H NMR using THF-d<sub>8</sub>.

boron catalysed silylation of *N,N*-dimethylaniline reported by Hou *et al.*<sup>10a</sup> and the silatranes reported by Miyaura *et al.*<sup>13</sup>). However, in the case of the latter, no product was recovered when purification of the crude mixture was attempted by column chromatography. Other substrates featuring nitrogen-containing directing groups, namely, 1-phenylpyrazole, 2-phenylpyridine, and 2-(*p*-tolyl)pyridine, were also successfully converted to the silylated products, except for triethoxysilane (Scheme 2). To our surprise, the silylation of 2-(*p*-tolyl)pyridine showed an unexpected selectivity shift when aromatic silanes were used instead of triethylsilane. In contrast to the previous examples, the directing group, *i.e.* the pyridine moiety, undergoes exclusive silylation of its C5–H bond. This rare selectivity has also been reported recently by Oestreich and co-workers.<sup>26</sup>

The intermolecular non-directed silylation of aromatic and heteroaromatic molecules was also achieved by employing an arene as the limiting reactant (3 equivalents of silane). Among these reactions, the regioselective silylation of naphthalene at the C2-position was also achieved. This is, to the extent of our knowledge, the first example of naphthalene functionalisation by catalytic C–H bond silylation. The silylation of *m*-xylene, thiophene, benzothiophene and 2-methylthiophene was also regioselective, which contrasts to the mixture of regioisomers obtained for fluoro-, chloro-, ethylbenzene and *sec*-butylbenzene using triethylsilane (Scheme 3). To our delight, the selective silylation of chlorobenzene to afford the *para* isomer exclusively was accomplished with PhMe<sub>2</sub>SiH.

The relative reactivity of the different silanes may be estimated from the results presented in Schemes 2 and 3. The least







Fig. 2 DFT calculated Gibbs free energy profile at 110 °C and a concentration of 1 M (in kcal mol<sup>-1</sup> and relative to 1 and the isolated molecules) for the Ir-catalysed silylation of 2-phenylpyridine with a hydrogen acceptor.

the acceptor and acceptor-less processes, respectively). The possibility of oxidative addition of the silane over the NHC–Ir(I) intermediate 7 was also studied; however, the resulting species (7') is 9.3 kcal mol<sup>-1</sup> less stable than that resulting from the oxidative addition of the C–H bond (9) and only 7.7 kcal mol<sup>-1</sup> more stable than 7. Therefore, 7' may be in equilibrium with 7 under the reaction conditions, thus allowing for the transformation of 7' into 9.

## Reactivity studies

**Reactivity of 1.** In the search for experimental evidence that would support the mechanism proposed above, several stoichiometric experiments were performed. The reaction of

complex 1 at room temperature with 1 equivalent of 2-phenylpyridine (Phpy), 2-thienylpyridine (Thpy), 2-(*p*-tolyl)pyridine (*p*-tolylpy) or 1-phenylimidazole (Phpz), with and without norbornene, afforded the corresponding cyclometalated derivatives: complexes 9 and 13–15 (Scheme 5). In this regard, the sluggish formation of complexes 9 and 13–15 in the presence of norbornene at room temperature, and the concomitant generation of norbornane, agrees with the calculated energy barrier (21.0 kcal mol<sup>-1</sup>) for the formation of intermediate 9.

All of the complexes were isolated as air stable solids and fully characterized by multinuclear NMR spectroscopy. In addition, the molecular structures of complexes 9 and 13 were determined by X-ray diffraction analysis on suitable crystals that



Fig. 3 DFT calculated Gibbs free energy profile at 110 °C and a concentration of 1 M (in kcal mol<sup>-1</sup> and relative to 1 and the isolated molecules) for the Ir-catalysed silylation of 2-phenylpyridine without a hydrogen acceptor.





Scheme 5 Synthesis of complexes 9 and 13–15.

were obtained by slow diffusion of diethyl ether into a solution of the corresponding complex in  $\text{CH}_2\text{Cl}_2$  (Fig. 4 and 5).

The most representative resonances in the  $^1\text{H}$  NMR are those in the highfield region, corresponding to the hydrido ligands, which shift upon cyclometallation of the substrate from  $\delta = -22.48$  ppm in **1** to  $\delta = -18.14$ ,  $-19.30$ ,  $-18.10$  and  $-19.70$  ppm in **9**, **13**, **14** and **15**, respectively.

Besides, APT, HSQC and HMBC NMR experiments support the metallation of the corresponding substrates, thereby confirming the directed C–H activation process.

The X-ray diffraction analysis provides valuable information that may shed light into the selectivity patterns observed in directed silylation. In both compounds the Ir(III) centre shows a distorted octahedral geometry with the cyclometalated ligand accommodated in the equatorial plane, *cis* to the IPr ligand. The pyridine moiety in the Phpy-1H and Thpy-1H ligands is situated



Fig. 4 ORTEP view of the cation  $[\text{Ir}(\text{H})(\text{IPr})(\text{Phpy-1H})(\text{py})_2]^+$  in  $9 \cdot \text{CH}_2\text{Cl}_2$  with a numbering scheme adopted. Most of the hydrogens are omitted for clarity and thermal ellipsoids are at 50% probability. Selected bond lengths (Å) and angles ( $^\circ$ ): C(1)–N(2) 1.375(4), C(1)–N(5) 1.376(4), C(1)–Ir(1) 2.019(4), C(30)–Ir(1) 2.017(3), N(37)–Ir(1) 2.186(3), N(42)–Ir(1) 2.138(3), N(48)–Ir(1) 2.194(3), N(2)–C(1)–N(5) 102.5(3), C(30)–Ir(1)–C(1) 99.60(14), C(30)–Ir(1)–N(42) 82.93(13), C(1)–Ir(1)–N(42) 168.91(12), C(30)–Ir(1)–N(37) 79.42(13), C(1)–Ir(1)–N(37) 101.11(13), N(42)–Ir(1)–N(37) 89.96(12), C(30)–Ir(1)–N(48) 164.74(12), C(1)–Ir(1)–N(48) 95.37(12), N(42)–Ir(1)–N(48) 81.81(11), N(37)–Ir(1)–N(48) 100.63(12).



Fig. 5 ORTEP view of the cation  $[\text{Ir}(\text{H})(\text{IPr})(\text{Thpy-1H})(\text{py})_2]^+$  in  $13 \cdot 1.5 \cdot \text{CH}_2\text{Cl}_2$  with a numbering scheme adopted. Most of the hydrogens are omitted for clarity and thermal ellipsoids are at 50% probability. Selected bond lengths (Å) and angles ( $^\circ$ ): C(1)–N(2) 1.375(5), C(1)–N(5) 1.382(5), C(1)–Ir(1) 2.007(4), C(30)–Ir(1) 2.013(4), N(36)–Ir(1) 2.195(4), N(41)–Ir(1) 2.146(4), N(47)–Ir(1) 2.176(4), N(2)–C(1)–N(5) 102.8(3), C(1)–Ir(1)–C(30) 97.21(17), C(1)–Ir(1)–N(41) 170.95(15), C(30)–Ir(1)–N(41) 83.69(16), C(1)–Ir(1)–N(47) 92.20(15), C(30)–Ir(1)–N(47) 170.58(16), N(41)–Ir(1)–N(47) 86.97(14), C(1)–Ir(1)–N(36) 100.97(15), C(30)–Ir(1)–N(36) 79.16(17), N(41)–Ir(1)–N(36) 88.05(13), N(47)–Ir(1)–N(36) 99.36(15).

*trans* to the hydride, thus allowing the two py ligands to sit *trans* to the IPr ligand and the metallated carbon atom.

The distorted geometry of **9** and **13** is attributable to the steric repulsion between the cumbersome side arms of IPr and the cyclometalated ligand. This causes the NHC ligand to move away from Phpy-1H (**9**) or Thpy-1H (**13**) (C(1)–Ir(1)–N(42) 168.91(12) and C(1)–Ir(1)–N(37) 101.11(13) for **9** or C(1)–Ir(1)–N(41) 170.95(15) and C(1)–Ir(1)–N(36) 100.97(15) for **13**) and closer to the apical py ligand (C(30)–Ir(1)–N(42) 82.93(13) for **9** or C(30)–Ir(1)–N(41) 83.69(16) for **13**). Moreover, the geometry of the NHC is also affected: (i) the yaw angle (in plane tilting of the NHC) is *ca.*  $10^\circ$  for **9** and **13**; (ii) the methyl ( $^i\text{Pr}$ ) group situated above the py moiety of the cyclometalated ligand shows a dihedral angle  $\text{C}_{\text{Ar}(\text{C}-\text{H})} \cdots \text{C}_{\text{ipso}(\text{C}-\text{iPr})} \cdots \text{C}_{\text{CH}(\text{iPr})} \cdots \text{C}_{\text{Me}(\text{iPr})}$  of *ca.*  $26^\circ$ , while the other  $^i\text{Pr}$  groups feature dihedral angles between  $40$  and  $57^\circ$ . Both structural parameters are indicative of the steric constraints originating from cyclometallation. On these grounds, an increase in steric hindrance in the system, as is the case for *p*-tolylpy, which would be exacerbated by the use of aromatic silanes, may lead to the de-coordination of the py moiety, reductive elimination and, eventually, oxidative addition of the C–H that affords the least encumbered species. The metallated intermediate that originates from the oxidative addition of the C5–H bond is the one that is situated in the methyl group furthest from the IPr ligand (see the py-silylation products described in Scheme 2).



The reaction of **1** with 1 equivalent of 2,2'-bipyridine (bipy) at room temperature in  $\text{CH}_2\text{Cl}_2$  affords complex  $[\text{Ir}(\text{bipy})(\text{H})_2(\text{IPr})(\text{py})][\text{BF}_4]$  (**16**) (Scheme 6), which shows no catalytic activity. This suggests that the presence of the chelating ligand, bipy, thwarts the activation of the arene, which consequently inhibits the catalytic activity of the complex. Moreover, the addition of pyridine (10 equivalents) to the reaction of Phpy with  $\text{Et}_3\text{SiH}$ , under the conditions described in Scheme 2, resulted in a significant decrease in catalytic activity. In this case, the  $^1\text{H}$  MNR spectrum of the crude mixture shows only a 57% conversion, which contrasts to the example reported in Scheme 2 (without added py) where total conversion was obtained from the crude mixture.

**Reactivity of the cyclometalated complexes.** The addition of 3 equivalents of triethylsilane to a solution of **9** in  $\text{CH}_2\text{Cl}_2$  at room temperature renders the starting complex unaltered, which is consistent with the higher temperatures required for the formation of the organosilane and the calculated energy barrier for this process ( $27.2 \text{ kcal mol}^{-1}$  from **9** to **11**<sup>‡</sup>). Attempts to identify reaction intermediates *in situ* by NMR spectroscopy in 1,1,2,2-tetrachloroethane- $d_2$  showed that no reaction takes place up to  $100^\circ\text{C}$ .

With the intention of finding support for the calculated mechanism, cyclometalated complexes **9** and **14** were employed as pre-catalysts under the reaction conditions described in Scheme 2. The reaction of Phpy with  $\text{Et}_3\text{SiH}$  catalysed by **9** and the reaction of *p*-tolylpy with  $\text{Ph}_2\text{MeSiH}$  catalysed by **14** gave the silylated products in 81% and 54% yield, respectively (almost identical yields compared to **1**). These experiments, together with the DFT calculations, seem to suggest that **9** may be a resting state that enters the catalytic cycle upon loss of a pyridine ligand.

Moreover, a complex related to **1**, namely  $[\text{Ir}(\text{CH}_3\text{-CN})(\text{H})(\text{IPr})(\text{Phpy-1H})(\text{PPhMe}_2)][\text{BF}_4]$  (**17**), which presents a  $\text{PPhMe}_2$  ligand *trans* to the NHC ligand and an acetonitrile ligand *cis* to the hydride ligand, instead of the apical and equatorial pyridine ligands in **1**, was prepared (Scheme 7). When complex **17** was used as a catalyst for the reaction of Phpy with  $\text{Et}_3\text{SiH}$ , under the reaction conditions described in Scheme 2, no silylated product was obtained. The fact that **17** is inactive towards the silylation of Phpy agrees with the proposed mechanism, since a labile position *trans* to the IPr ligand is required for the end-on coordination of the silane. Complex **17** features a strongly coordinating ligand *trans* to the NHC ligand which blocks this coordination site, while the availability of an easily

Scheme 7 Synthesis of complex **17**.


accessible position *cis* to the hydride ligand does not seem to play any role in the reaction, which further supports the calculated mechanism. In this regard, the use of the IPr ligand probably facilitates the dissociation of the *trans* positioned py ligand (NHCs feature stronger *trans* effects than the ligands usually employed for these transformations),<sup>34</sup> thus generating an available coordination site that may account for the unexpected activity of this system towards less reactive silanes, *e.g.*  $(\text{EtO})_3\text{SiH}$ .

In summary, the reactivity shown by complex **1** and the cyclometalated complexes **9** and **13–15** is in accordance with the calculated reaction profile for a variety of reasons: (i) the addition of an arene to **1** gives the corresponding resting states of the catalytic cycle (complexes **9** and **13–15**), which exhibit virtually identical catalytic activity compared to **1**. Furthermore, these species become inactive if the position *trans* to the NHC ligand, where silane coordination should take place, is blocked with a phosphane ligand; (ii) the reaction rates are significantly reduced in the presence of excess py, moreover, when the two coordination sites *trans* to the hydrides in **1** are blocked with bipy, the resulting complex, **16**, is not a competent catalyst for the silylation of Phpy with  $\text{Et}_3\text{SiH}$ ; (iii) complex **9** only reacts with the silane at high temperatures to directly afford the silylated product, which is in agreement with the  $\sigma$ -CAM reaction being the rate limiting step followed by a downslope process toward the organosilane **1**.

Additionally, an experiment employing  $\text{PhMe}_2\text{SiD}$  and Phpy showed no deuterium incorporation into the silylated product, which also agrees with the proposed mechanism.

## Conclusions

We have prepared a well-defined Ir(III) complex that acts as an efficient pre-catalyst for the intermolecular silylation of a wide variety of arenes and heteroarenes with and without a directing group. Moreover, in view of expanding the synthetic applicability of this reaction the (hetero)arene was successfully employed in all cases as the limiting reagent. This process is compatible with the use of several hydrosilanes, including examples with  $\text{Et}_3\text{SiH}$ ,  $\text{Ph}_2\text{MeSiH}$ ,  $\text{PhMe}_2\text{SiH}$ ,  $\text{Ph}_3\text{SiH}$  and  $(\text{EtO})_3\text{SiH}$ . It is worth noting that, in certain cases, the presence of aromatic substituents in the hydrosilanes triggers unprecedented selectivity patterns worthy of a more in-depth study in the future. The use of **1** as a pre-catalyst also permits the efficient bisarylation of bis(hydrosilane)s by directed or non-directed silylation of C–H bonds, which may be utilised as a new tool for the synthesis of conjugated organosilicon materials.

Scheme 6 Synthesis of complex **16**.

The mechanistic studies performed in this work point towards an Ir(III)/Ir(I) mechanism where the dehydrogenation of the Ir(III) species **1** generates a very electron-rich NHC-Ir(I) intermediate **6** that allows for the facile activation of the arene C–H bond.

## Experimental

### General considerations

All experiments were carried out under an inert atmosphere using standard Schlenk techniques. The solvents were dried by known procedures and distilled under argon prior to use or obtained oxygen- and water-free from a Solvent Purification System (Innovative Technologies). The starting complex was prepared according to a literature procedure [Ir(COD)(IPr)(acetone)][BF<sub>4</sub>]<sup>25f</sup>. All other commercially available starting materials were purchased from Sigma-Aldrich, Merck and J. T. Baker and were used without further purification. H<sub>2</sub> gas (>99.5%) was obtained from Infracore.

<sup>1</sup>H, <sup>13</sup>C{<sup>1</sup>H}, <sup>19</sup>F, <sup>1</sup>H-<sup>29</sup>Si HMBC, <sup>1</sup>H-<sup>13</sup>C HMBC, <sup>1</sup>H-<sup>13</sup>C HSQC and <sup>1</sup>H-<sup>1</sup>H COSY NMR spectra were recorded either on a Bruker ARX 300 MHz or a Bruker Avance 400 MHz instrument. Chemical shifts (expressed in parts per million) are referenced to residual solvent peaks for <sup>1</sup>H and <sup>13</sup>C{<sup>1</sup>H}, and to an external reference of CFCl<sub>3</sub> for <sup>19</sup>F. Coupling constants, *J*, are given in Hz. Spectral assignments were achieved by combination of <sup>1</sup>H-<sup>1</sup>H COSY, <sup>13</sup>C APT and 1H-<sup>13</sup>C HSQC/HMBC experiments. C, H, and N analyses were carried out in a Perkin-Elmer 2400 CHNS/O analyser. GC-MS spectra were recorded on a Hewlett-Packard GC-MS system. Column chromatography was performed using silica gel (70–230 mesh).

### Synthesis and characterization of complexes **9** and **13–17**†

**[Ir(H)(IPr)(py)<sub>2</sub>][BF<sub>4</sub>]** (**1**). A solution of [Ir(COD)(IPr)(acetone)][BF<sub>4</sub>] (300 mg, 0.36 mmol) in acetone (10 mL) was reacted with pyridine (0.5 mL) and stirred under a hydrogen atmosphere (1 bar) for 1 h. The resulting pale yellow solution was concentrated to ca. 0.5 mL, and treated with diethyl ether to afford a white solid. The solid was separated by decantation, washed with diethyl ether and dried *in vacuo*. A CH<sub>2</sub>Cl<sub>2</sub> solution (0.4 mL) of this solid (12 mg) was layered with diethyl ether (5 mL) and stored in a glove box at room temperature to afford crystals suitable for X-ray diffraction. Yield: 72% (234 mg, 0.25 mmol). <sup>1</sup>H NMR (300 MHz, CD<sub>2</sub>Cl<sub>2</sub>, 263 K): δ 8.14 ppm (d, *J*<sub>H–H</sub> = 5.0, 4H, H<sub>o-py-a</sub>); 7.84 (d, *J*<sub>H–H</sub> = 5.7, 2H, H<sub>o-py-b</sub>); 7.71 (t, *J*<sub>H–H</sub> = 7.6, 2H, H<sub>p-py-a</sub>); 7.66 (t, *J*<sub>H–H</sub> = 7.5, 1H, H<sub>p-py-b</sub>); 7.30 (t, *J*<sub>H–H</sub> = 7.7, 2H, H<sub>p-IPr</sub>); 7.11 (d, *J*<sub>H–H</sub> = 7.7, 4H, H<sub>m-IPr</sub>); 7.09 (dd, *J*<sub>H–H</sub> = 7.6, 5.0, 4H, H<sub>m-py-a</sub>); 7.07 (s, 2H, =CHN); 6.96 (dd, *J*<sub>H–H</sub> = 7.5, 5.7, 4H, H<sub>m-py-b</sub>); 2.87 (sept, *J*<sub>H–H</sub> = 6.9, 4H, CHMe<sub>IPr</sub>); 1.16 and 1.11 (both d, *J*<sub>H–H</sub> = 6.9, 24H, CHMe<sub>IPr</sub>); –22.48 (s, 2H, Ir–H). <sup>13</sup>C {<sup>1</sup>H}-APT, HSQC and HMBC NMR (75 MHz, CD<sub>2</sub>Cl<sub>2</sub>, 298 K): δ 155.3 ppm (s, C<sub>o-py-b</sub>); 154.7 (s, Ir–C<sub>IPr</sub>); 153.5 (s, C<sub>o-py-a</sub>); 145.6 (s, C<sub>q-IPr</sub>); 138.1 (s, C<sub>q-N</sub>); 136.8 (s, C<sub>p-py-b</sub>); 136.6 (s, C<sub>p-py-a</sub>); 129.9 (s, C<sub>p-IPr</sub>); 125.9 (s, C<sub>m-py-a</sub>); 125.7 (s, C<sub>m-py-b</sub>); 123.8 (s, C<sub>m-IPr</sub>); 28.9 (s, CHMe<sub>IPr</sub>); 25.9 and 21.6 (both s, CHMe<sub>IPr</sub>). <sup>19</sup>F NMR (400 NMR, CD<sub>2</sub>Cl<sub>2</sub>, 298 K): δ –155.2 ppm (s, BF<sub>4</sub>). Anal. calcd.

for C<sub>42</sub>H<sub>54</sub>BF<sub>4</sub>IrN<sub>5</sub> (908.40 + CH<sub>2</sub>Cl<sub>2</sub>): C, 52.02; H, 5.69; N, 7.05%. Found: C, 51.95; H, 5.85; N, 6.85%.

**[Ir(H)(IPr)(Phpy-1H)(py)<sub>2</sub>][BF<sub>4</sub>]** (**9**). 2-Phenylpyridine (19 μL, 0.13 mmol) was added to a solution of **1** (120 mg, 0.13 mmol) in 5 mL of dichloromethane and the resulting solution was stirred for 40 min at room temperature. After this time, the resulting light yellow solution was concentrated to ca. 0.5 mL and diethyl ether was added to give a white solid. The solid thus formed was separated by decantation, washed with diethyl ether and dried *in vacuo*. Yield: 63% (82 mg, 0.08 mmol). A CH<sub>2</sub>Cl<sub>2</sub> solution (0.3 mL) of the solid (10 mg) was layered with diethyl ether (5 mL) and stored in a glove box at room temperature to afford crystals suitable for X-ray diffraction. <sup>1</sup>H NMR (300 MHz, CD<sub>2</sub>Cl<sub>2</sub>, 298 K): δ 8.24 ppm (d, *J*<sub>H–H</sub> = 5.1, 2H, H<sub>o-py-a</sub>); 7.92 (t, *J*<sub>H–H</sub> = 6.6, 1H, H<sub>p-py-a</sub>); 7.91 (d, *J*<sub>H–H</sub> = 7.9, 1H, H<sub>3-py</sub>); 7.72 (dd, *J*<sub>H–H</sub> = 7.9, 6.7, 1H, H<sub>4-py</sub>); 7.55 (d, *J*<sub>H–H</sub> = 7.9, 1H, H<sub>o-Ph</sub>); 7.49 (t, *J*<sub>H–H</sub> = 6.7, 1H, H<sub>p-py-b</sub>); 7.47 (t, *J*<sub>H–H</sub> = 6.6, 2H, H<sub>p-IPr</sub>); 7.40 (d, *J*<sub>H–H</sub> = 5.6, 1H, H<sub>6-py</sub>); 7.37 (d, *J*<sub>H–H</sub> = 6.0, 2H, H<sub>o-py-b</sub>); 7.31 (dd, *J*<sub>H–H</sub> = 6.6, 5.1, 2H, H<sub>m-py-a</sub>); 7.11 (d, *J*<sub>H–H</sub> = 6.6, 4H, H<sub>m-IPr</sub>); 7.09 (s, 2H, =CHN); 6.78 (dd, *J*<sub>H–H</sub> = 6.7, 5.6, 1H, H<sub>5-py</sub>); 6.77 (dd, *J*<sub>H–H</sub> = 6.7, 6.0, 2H, H<sub>m-py-b</sub>); 6.75 (dd, *J*<sub>H–H</sub> = 7.9, 7.7, 1H, H<sub>m1-Ph</sub>); 6.46 (dd, *J*<sub>H–H</sub> = 8.2, 7.7, 1H, H<sub>p-Ph</sub>); 5.97 (d, *J*<sub>H–H</sub> = 8.2, 1H, H<sub>m2-Ph</sub>); 2.87 and 2.25 (both sept, *J*<sub>H–H</sub> = 6.6, 4H, CHMe<sub>IPr</sub>); 1.11, 1.05, 1.02, and 0.43 (all d, *J*<sub>H–H</sub> = 6.6, CHMe<sub>IPr</sub>); –18.14 (s, 1H, Ir–H). <sup>13</sup>C {<sup>1</sup>H}-APT, HSQC and HMBC NMR (75 MHz, CD<sub>2</sub>Cl<sub>2</sub>, 298 K): δ 165.1 ppm (s, C<sub>2-py</sub>); 153.5 (s, C<sub>o-py-a</sub>); 152.7 (s, C<sub>o-py-b</sub>); 150.8 (s, Ir–C<sub>IPr</sub>); 148.2 (s, C<sub>6-py</sub>); 146.6 and 146.4 (both s, C<sub>q-IPr</sub>); 145.3 (s, Ir–C<sub>Ph</sub>); 143.6 (s, C<sub>q-Ph</sub>); 143.4 (s, C<sub>m2-Ph</sub>); 138.0 (s, C<sub>p-py-a</sub>); 137.1 (s, C<sub>q-N</sub>); 137.0 (s, C<sub>p-py-b</sub>); 136.8 (s, C<sub>4-py</sub>); 130.2 (s, C<sub>p-IPr</sub>); 129.5 (s, C<sub>p-Ph</sub>); 126.2 (s, C<sub>m-py-a</sub>); 125.7 (s, C<sub>m-py-b</sub>); 125.6 (s, =CHN); 124.4 and 123.7 (both s, C<sub>m-IPr</sub>); 123.6 (s, C<sub>o-Ph</sub>); 123.0 (s, C<sub>5-py</sub>); 121.4 (s, C<sub>m1-Ph</sub>); 119.9 (s, C<sub>3-py</sub>); 29.0 and 28.9 (s, CHMe<sub>IPr</sub>); 26.9, 26.2, 21.3, and 20.8 (all, s, CHMe<sub>IPr</sub>). <sup>19</sup>F NMR (400 NMR, CD<sub>2</sub>Cl<sub>2</sub>, 298 K): δ –152.5 ppm (s, BF<sub>4</sub>). Anal. calcd. for C<sub>48</sub>H<sub>55</sub>IrN<sub>5</sub>BF<sub>4</sub> (981.41): C, 58.77; H, 5.65; N, 7.14%. Found: C, 58.70; H, 5.66; N, 7.16%.

**[Ir(H)(IPr)(Thpy-1H)(py)<sub>2</sub>][BF<sub>4</sub>]** (**13**). 2-Thienylpyridine (21 mg, 0.13 mmol) was added to a solution of **1** (120 mg, 0.13 mmol) in 5 mL of dichloromethane and the resulting solution was stirred for 40 min at room temperature. After this time, the resulting light yellow solution was concentrated to ca. 0.5 mL and diethyl ether was added to give a white solid. The solid thus formed was separated by decantation, washed with diethyl ether and dried *in vacuo*. Yield: 67% (87 mg, 0.09 mmol). <sup>1</sup>H NMR (400 MHz, CD<sub>2</sub>Cl<sub>2</sub>, 283 K): δ 8.27 ppm (d, *J*<sub>H–H</sub> = 5.3, 2H, H<sub>o-py-a</sub>); 7.92 (t, *J*<sub>H–H</sub> = 7.8, 1H, H<sub>p-py-a</sub>); 7.63 (dd, *J*<sub>H–H</sub> = 7.9, 6.9, 1H, H<sub>4-py</sub>); 7.49 (t, *J*<sub>H–H</sub> = 7.6, 2H, H<sub>p-IPr</sub>); 7.48 (d, *J*<sub>H–H</sub> = 7.9, 1H, H<sub>3-py</sub>); 7.47 (t, *J*<sub>H–H</sub> = 7.1, 1H, H<sub>p-py-b</sub>); 7.30 (dd, *J*<sub>H–H</sub> = 7.8, 5.3, 2H, H<sub>m-py-a</sub>); 7.29 (d, *J*<sub>H–H</sub> = 6.2, 1H, H<sub>o-py-b</sub>); 7.25 and 7.13 (both d, *J*<sub>H–H</sub> = 7.6, 4H, H<sub>m-IPr</sub>); 7.20 (d, *J*<sub>H–H</sub> = 5.5, 1H, H<sub>6-py</sub>); 7.11 (s, 2H, =CHN); 6.94 and 5.48 (both d, *J*<sub>H–H</sub> = 4.7, 2H, H<sub>Th</sub>); 6.78 (dd, *J*<sub>H–H</sub> = 7.1, 6.2, 2H, H<sub>m-py-b</sub>); 6.66 (dd, *J*<sub>H–H</sub> = 6.9, 5.5, 1H, H<sub>5-py</sub>); 2.86 and 2.28 (both sept, *J*<sub>H–H</sub> = 6.9, 4H, CHMe<sub>IPr</sub>); 1.13, 1.06, 1.05, and 0.55 (all d, *J*<sub>H–H</sub> = 6.9, 24H, CHMe<sub>IPr</sub>); –19.30 (s, 1H, Ir–H). <sup>13</sup>C {<sup>1</sup>H}-APT, HSQC and HMBC NMR (100 MHz, CD<sub>2</sub>Cl<sub>2</sub>, 298 K): δ 160.9 ppm (s, C<sub>2-py</sub>); 154.0 (s, C<sub>o-py-a</sub>); 152.4 (s, C<sub>o-py-b</sub>); 150.1 (s, Ir–C<sub>IPr</sub>); 148.5 (s, Ir–C<sub>Th</sub>); 148.4 (s, C<sub>6-py</sub>); 146.6 and 146.2 (both s, C<sub>q-IPr</sub>); 140.0 and 128.0 (both s, C<sub>Th</sub>); 138.1 (s, C<sub>p-py-a</sub>); 137.3 (s,



C<sub>4-py</sub>); 137.1 (s, C<sub>qN</sub>); 137.0 (s, C<sub>p-py-b</sub>); 136.8 (s, C<sub>q-Th</sub>); 130.3 (s, C<sub>p-IPr</sub>); 126.3 (s, C<sub>m-py-a</sub>); 125.5 (s, C<sub>m-py-b</sub>); 125.4 and 124.3 (both s, C<sub>m-IPr</sub>); 123.8 (s, =CHN); 120.4 (s, C<sub>5-py</sub>); 119.2 (s, C<sub>3-py</sub>); 29.1 and 28.9 (s, CHMe<sub>IPr</sub>); 27.0, 26.3, 21.4, and 20.7 (all, s, CHMe<sub>IPr</sub>). <sup>19</sup>F NMR (400 MHz, CD<sub>2</sub>Cl<sub>2</sub>, 298 K): δ -153.0 ppm (s, BF<sub>4</sub>). Anal. calcd. for C<sub>46</sub>H<sub>53</sub>IrN<sub>5</sub>BF<sub>4</sub> (995.40): C, 55.98; H, 5.41; N, 7.10%. Found: C, 55.93; H, 5.46; N 7.10%.

**[Ir(H)(IPr)(py)<sub>2</sub>(p-tolylpy-1H)][BF<sub>4</sub>] (14).** 2-(p-Tolyl)pyridine (22 mg, 0.13 mmol) was added to a solution of **1** (120 mg, 0.13 mmol) in 5 mL of dichloromethane and the resulting solution was stirred for 40 min at room temperature. After this time, the resulting light yellow solution was concentrated to ca. 0.5 mL and diethyl ether was added to give a light yellow solid. The solid thus formed was separated by decantation, washed with diethyl ether and dried *in vacuo*. Yield: 67% (88 mg, 0.09 mmol). <sup>1</sup>H NMR (400 MHz, CD<sub>2</sub>Cl<sub>2</sub>, 298 K): δ 8.20 ppm (d, J<sub>H-H</sub> = 5.1, 2H, H<sub>o-py-a</sub>); 7.93 (t, J<sub>H-H</sub> = 6.9, 1H, H<sub>p-py-a</sub>); 7.90 (d, J<sub>H-H</sub> = 7.6, 1H, H<sub>3-py</sub>); 7.69 (dd, J<sub>H-H</sub> = 7.6, 6.9, 1H, H<sub>4-py</sub>); 7.49 (t, J<sub>H-H</sub> = 6.9, 1H, H<sub>p-py-b</sub>); 7.48 (both t, J<sub>H-H</sub> = 7.9, 2H, H<sub>p-IPr</sub>); 7.46 (d, J<sub>H-H</sub> = 8.2, 1H, H<sub>o-ph</sub>); 7.36 (br, 2H, H<sub>o-py-b</sub>); 7.33 (d, J<sub>H-H</sub> = 5.8, 1H, H<sub>6-py</sub>); 7.30 (dd, J<sub>H-H</sub> = 6.9, 5.1, 2H, H<sub>m-py-a</sub>); 7.23 and 7.09 (both d, J<sub>H-H</sub> = 7.9, 4H, H<sub>m-IPr</sub>); 7.22 (s, 2H, =CHN); 6.79 (dd, J<sub>H-H</sub> = 6.9, 5.3, 2H, H<sub>m-py-b</sub>); 6.71 (dd, J<sub>H-H</sub> = 6.9, 5.8, 1H, H<sub>5-py</sub>); 6.58 (d, J<sub>H-H</sub> = 8.2, 1H, H<sub>m1-ph</sub>); 5.75 (s, 1H, H<sub>m2-ph</sub>); 2.91 and 2.20 (both br, 4H, CHMe<sub>IPr</sub>); 1.95 (s, 3H, Me), 1.15, 1.04, 1.03, and 0.37 (all d, J<sub>H-H</sub> = 6.2, 24H, CHMe<sub>IPr</sub>); -18.10 (s, Ir-H). <sup>13</sup>C {<sup>1</sup>H}-APT, HSQC and HMBC NMR (100 MHz, CD<sub>2</sub>Cl<sub>2</sub>, 298 K): δ 165.0 ppm (s, C<sub>2-py</sub>); 153.5 (s, C<sub>o-py-a</sub>); 152.4 (s, C<sub>o-py-b</sub>); 151.2 (s, C<sub>IPr-IPr</sub>); 147.9 (s, C<sub>6-py</sub>); 146.5 and 146.4 (both s, C<sub>q-IPr</sub>); 145.2 (s, Ir-C<sub>Ph</sub>); 143.9 (s, C<sub>m2-ph</sub>); 141.1 (s, C<sub>q-ph</sub>); 139.3 (s, C<sub>q-Me</sub>); 138.1 (s, C<sub>p-py-a</sub>); 137.0 (s, C<sub>p-py-b</sub>); 136.9 (s, C<sub>qN</sub>); 136.6 (s, C<sub>4-py</sub>); 130.3 (s, C<sub>p-IPr</sub>); 126.1 (s, C<sub>m-py-a</sub>); 125.7 (s, C<sub>m-py-b</sub>); 125.2 and 124.2 (both s, C<sub>m-IPr</sub>); 123.7 (s, =CHN); 123.6 (s, C<sub>o-ph</sub>); 122.8 (s, C<sub>m1-ph</sub>); 122.5 (s, C<sub>5-py</sub>); 119.7 (s, C<sub>3-py</sub>); 29.0 and 28.9 (both s, CHMe<sub>IPr</sub>); 26.9, 26.2, 21.3, and 20.3 (all s, CHMe<sub>IPr</sub>); 21.4 (s, Me). <sup>19</sup>F NMR (400 MHz, CD<sub>2</sub>Cl<sub>2</sub>, 298 K): δ -152.9 ppm (s, BF<sub>4</sub>). Anal. calcd. for C<sub>49</sub>H<sub>57</sub>IrN<sub>5</sub>BF<sub>4</sub> (995.43): C, 59.15; H, 5.77; N 7.04%. Found: C, 59.15; H, 5.76; N, 7.10%.

**[Ir(H)(IPr)(Phpz-1H)(py)<sub>2</sub>][BF<sub>4</sub>] (15).** 1-Phenylpyrazole (17 μL, 0.13 mmol) was added to a solution of **1** (120 mg, 0.13 mmol) in 5 mL of dichloromethane and the resulting solution was stirred for 1 h at room temperature. After this time, the resulting light yellow solution was concentrated to ca. 0.5 mL and diethyl ether was added to give a white solid. The solid thus formed was separated by decantation, washed with diethyl ether and dried *in vacuo*. Yield: 65% (77 mg, 0.09 mmol). <sup>1</sup>H NMR (400 MHz, CD<sub>2</sub>Cl<sub>2</sub>, 283 K): δ 8.30 ppm (d, J<sub>H-H</sub> = 5.1, 2H, H<sub>o-py-a</sub>); 7.81 (d, J<sub>H-H</sub> = 2.9, 1H, H<sub>5-pz</sub>); 7.80 (t, J<sub>H-H</sub> = 6.8, 1H, H<sub>p-py-a</sub>); 7.44 (t, J<sub>H-H</sub> = 8.0, 2H, H<sub>p-IPr</sub>); 7.36 (t, J<sub>H-H</sub> = 6.9, 1H, H<sub>p-py-b</sub>); 7.35 (d, J<sub>H-H</sub> = 5.4, 2H, H<sub>o-py-b</sub>); 7.21 (dd, J<sub>H-H</sub> = 6.8, 5.1, 2H, H<sub>m-py-a</sub>); 7.14 (d, J<sub>H-H</sub> = 1.9, 1H, H<sub>3-pz</sub>); 7.08 (s, 2H, =CHN); 7.07 (d, J<sub>H-H</sub> = 8.0, 4H, H<sub>m-IPr</sub>); 6.92 (d, J<sub>H-H</sub> = 7.6, 1H, H<sub>o-ph</sub>); 6.79 (dd, J<sub>H-H</sub> = 7.6, 7.1, 1H, H<sub>m1-ph</sub>); 6.76 (d, J<sub>H-H</sub> = 7.4, 1H, H<sub>m2-ph</sub>); 6.71 (dd, J<sub>H-H</sub> = 6.9, 2H, H<sub>m-py-b</sub>); 6.69 (dd, J<sub>H-H</sub> = 7.4, 7.1, 1H, H<sub>p-ph</sub>); 6.45 (dd, J<sub>H-H</sub> = 2.9, 1.9, 1H, H<sub>4-pz</sub>); 2.85 and 2.49 (both sept, J<sub>H-H</sub> = 6.9, 4H, CHMe<sub>IPr</sub>); 1.12, 1.09, 1.02, and 0.76 (all d, J<sub>H-H</sub> = 6.9, CHMe<sub>IPr</sub>); -19.70 (s, 1H, Ir-H). <sup>13</sup>C {<sup>1</sup>H}-APT, HSQC and

HMBC NMR (100 MHz, CD<sub>2</sub>Cl<sub>2</sub>, 283 K): δ 154.6 ppm (s, C<sub>o-py-a</sub>); 152.0 (s, C<sub>o-py-b</sub>); 149.1 (s, Ir-C<sub>IPr</sub>); 146.4 and 146.0 (both s, C<sub>q-IPr</sub>); 143.9 (s, Ir-C<sub>Ph</sub>); 143.0 (s, C<sub>m2-ph</sub>); 138.7 (s, C<sub>3-pz</sub>); 137.6 (s, C<sub>p-py-a</sub>); 136.9 (s, C<sub>p-py-b</sub>); 130.0 (s, C<sub>p-IPr</sub>); 128.5 (s, C<sub>q-ph</sub>); 126.4 (s, C<sub>5-pz</sub>); 126.3 (s, C<sub>m-py-a</sub>); 126.2 (s, C<sub>p-ph</sub>); 125.3 (s, C<sub>m-py-b</sub>); 125.2 (s, =CHN); 123.8 and 123.6 (both s, C<sub>m-IPr</sub>); 122.6 (s, C<sub>m1-ph</sub>); 111.1 (s, C<sub>o-ph</sub>); 107.6 (s, C<sub>4-pz</sub>); 29.1 and 28.9 (both s, CHMe<sub>IPr</sub>); 26.8, 26.3, 21.2, and 21.2 (all s, CHMe<sub>IPr</sub>). Anal. calcd. for C<sub>46</sub>H<sub>55</sub>BF<sub>4</sub>IrN<sub>6</sub> (971.41 + 0.5·CH<sub>2</sub>Cl<sub>2</sub>): C, 55.11; H, 5.57; N, 8.29%. Found: C, 55.08; H, 5.85; N, 8.61%.

**[Ir(bipy)(H)<sub>2</sub>(IPr)(py)]BF<sub>4</sub> (16).** 2,2'-Bipyridine (16 mg, 0.10 mmol) was added to a solution of **1** (80 mg, 0.10 mmol) in 5 mL of dichloromethane. The resulting solution was stirred for 30 min at room temperature. After this time, the resulting yellow solution was concentrated to ca. 0.5 mL and diethyl ether was added to give a yellow solid. The solid was separated by decantation, washed with diethyl ether and dried *in vacuo*. Yield: 79% (69 mg, 0.0764 mmol). <sup>1</sup>H NMR (400 MHz, CD<sub>2</sub>Cl<sub>2</sub>, 298 K): δ 8.67 ppm (d, J<sub>H-H</sub> = 8.1, 2H, H<sub>m2-dipy</sub>); 8.56 (d, J<sub>H-H</sub> = 6.1, 2H, H<sub>o-py</sub>); 8.42 (dd, J<sub>H-H</sub> = 8.1, 7.8, 2H, H<sub>p-dipy</sub>); 8.29 (t, J<sub>H-H</sub> = 7.6, 2H, H<sub>p-IPr</sub>); 8.05 (t, J<sub>H-H</sub> = 7.6, 1H, H<sub>p-py</sub>); 7.97 (d, J<sub>H-H</sub> = 7.6, 4H, H<sub>m-IPr</sub>); 7.80 (d, J<sub>H-H</sub> = 5.1, 2H, H<sub>o-dipy</sub>); 7.67 (dd, J<sub>H-H</sub> = 7.8, 5.1, 2H, H<sub>m1-dipy</sub>); 7.54 (s, 2H, =CHN); 7.43 (dd, J<sub>H-H</sub> = 7.6, 6.1, 2H, H<sub>m-py</sub>); 3.28 (sept, J<sub>H-H</sub> = 6.9, 4H, CHMe<sub>IPr</sub>); 1.69 and 1.50 (both d, J<sub>H-H</sub> = 6.9, 24H, CHMe<sub>IPr</sub>); -19.80 (s, 2H, Ir-H). <sup>13</sup>C {<sup>1</sup>H}-APT, HSQC and HMBC NMR (75 MHz, CD<sub>2</sub>Cl<sub>2</sub>, 298 K): δ 156.3 ppm (s, C<sub>q-dipy</sub>); 155.4 (s, C<sub>o-py</sub>); 153.0 (s, C<sub>o-dipy</sub>); 150.5 (s, Ir-C<sub>IPr</sub>); 147.4 (s, C<sub>q-IPr</sub>); 137.0 (s, C<sub>p-dipy</sub>); 136.9 (s, C<sub>qN</sub>); 136.7 (s, C<sub>p-py</sub>); 130.1 (s, C<sub>p-IPr</sub>); 127.0 (s, C<sub>m1-dipy</sub>); 125.1 (s, C<sub>m-py</sub>); 124.5 (s, C<sub>m-IPr</sub>); 123.5 (s, =CHN); 123.1 (s, C<sub>m2-dipy</sub>); 28.8 (s, CHMe<sub>IPr</sub>); 25.5 and 21.3 (s, CHMe<sub>IPr</sub>). <sup>19</sup>F NMR (400 MHz, CD<sub>2</sub>Cl<sub>2</sub>, 298 K): δ -153.1 ppm (s, BF<sub>4</sub>). Anal. calcd. for C<sub>42</sub>H<sub>51</sub>BF<sub>4</sub>IrN<sub>5</sub> (905.38): C, 55.75; H, 5.68; N, 7.74%. Found: C, 56.24; H, 5.73; N 7.59%.

**[Ir(CH<sub>3</sub>CN)(H)(IPr)(Phpy-1H)(PPhMe<sub>2</sub>)]BF<sub>4</sub> (17).** A solution of [Ir(COD)(IPr)(acetone)][BF<sub>4</sub>] (150 mg, 0.18 mmol) in acetonitrile (5 mL) was stirred under a hydrogen atmosphere (1 bar) for 1 h. The solvent was removed under reduced pressure and the remaining pale yellow residue was redissolved in dichloromethane (5 mL). Subsequently, the resulting solution was treated with dimethylphenylphosphine (0.19 mmol, 27 μL) and allowed to react at room temperature for 30 min. Then, 1-phenylpyrazole (25 μL, 0.19 mmol) was added to the solution and stirred at room temperature for 1 h. The resulting pale yellow solution was filtered through Celite, concentrated to ca. 0.5 mL and treated with diethyl ether to afford a white solid. The solid was separated by decantation, washed with diethyl ether, and dried *in vacuo*. Yield: 64% (115 mg, 0.11 mmol). <sup>1</sup>H NMR (400 MHz, CD<sub>2</sub>Cl<sub>2</sub>, 298 K): δ 7.86 ppm (d, J<sub>H-H</sub> = 5.4, 1H, H<sub>6-py</sub>); 7.53 (d, J<sub>H-H</sub> = 7.9, 1H, H<sub>3-py</sub>); 7.47 (dd, J<sub>H-H</sub> = 7.9, 6.8, 1H, H<sub>4-py</sub>); 7.46 (d, J<sub>H-H</sub> = 7.6, 1H, H<sub>o-phpy</sub>); 7.45 (t, J<sub>H-H</sub> = 7.7, 2H, H<sub>p-IPr</sub>); 7.38 and 7.04 (both d, J<sub>H-H</sub> = 7.7, 4H, H<sub>m-IPr</sub>); 7.25 (t, J<sub>H-H</sub> = 7.2, 1H, H<sub>p-ph</sub>); 7.16 (ddd, J<sub>H-H</sub> = 7.8, 7.2, J<sub>H-P</sub> = 2.1, 2H, H<sub>m-ph</sub>); 7.07 (s, 2H, =CHN); 6.92 (dd, J<sub>H-H</sub> = 7.6, 7.1, H<sub>m1-phpy</sub>); 6.81 (dd, J<sub>H-H</sub> = 7.4, 7.1, 1H, H<sub>p-phpy</sub>); 6.72 (dd, J<sub>H-P</sub> = 9.7, J<sub>H-H</sub> = 7.8, 2H, H<sub>o-ph</sub>); 6.69 (d, J<sub>H-H</sub> = 7.4, 1H, H<sub>o-phpy</sub>); 6.62 (dd, J<sub>H-H</sub> = 6.8, 5.4, 1H, H<sub>5-py</sub>); 2.55 and 2.41 (both sept, J<sub>H-H</sub> = 6.8, 4H, CHMe<sub>IPr</sub>); 2.09 (s, 3H, MeCN); 1.35, 1.14, 1.02, and 0.86 (all d, J<sub>H-H</sub> = 6.8, 24H,



CHMe<sub>IPr</sub>); 1.23 and 0.57 (both d,  $J_{H-P} = 9.7$ , 6H, PMe);  $-18.1$  (d,  $J_{H-P} = 17.9$ , IrH). <sup>13</sup>C {<sup>1</sup>H}-APT, HSQC and HMBC NMR (75 MHz, CD<sub>2</sub>Cl<sub>2</sub>, 298 K):  $\delta$  163.5 ppm (s, C<sub>2-py</sub>); 163.3 (d,  $J_{H-P} = 118.7$ , Ir-C<sub>IPr</sub>); 149.4 (s, C<sub>6-py</sub>); 145.9 and 145.2 (both s, C<sub>q-IPr</sub>); 143.9 (d,  $J_{H-P} = 2.8$ , C<sub>q-Phpy</sub>); 143.0 (s, C<sub>m2-Phpy</sub>); 142.8 (d,  $J_{H-P} = 11.7$ , Ir-C<sub>Ph</sub>); 137.4 (s, C<sub>qN</sub>); 135.5 (s, C<sub>4-py</sub>); 132.8 (d,  $J_{H-P} = 48.8$ , C<sub>q-Ph</sub>); 130.3 (s, C<sub>p-IPr</sub>); 129.9 (s, C<sub>p-Phpy</sub>); 129.1 (d,  $J_{H-P} = 2.5$ , C<sub>p-Ph</sub>); 129.0 (d,  $J_{H-P} = 8.5$ , C<sub>m-Ph</sub>); 128.1 (d,  $J_{H-P} = 9.2$ , C<sub>o-Ph</sub>); 125.2 and 125.1 (both s, =CHN); 123.9 (s, C<sub>o-Phpy</sub>); 123.9 and 123.4 (both s, C<sub>m-IPr</sub>); 122.4 (s, C<sub>5-py</sub>); 120.7 (s, C<sub>m1-Phpy</sub>); 118.7 (s, MeCN); 118.6 (s, C<sub>3-py</sub>); 28.5 and 28.4 (both s, CHMe<sub>IPr</sub>); 26.8, 25.3, 22.8, and 21.5 (all s, CHMe<sub>IPr</sub>); 13.8 and 9.3 (both d,  $J_{H-P} = 41.5$ , PMe); 3.4 (s, MeCN). <sup>31</sup>P NMR (100 NMR, CD<sub>2</sub>Cl<sub>2</sub>, 298 K):  $\delta$   $-28.0$  ppm. <sup>19</sup>F NMR (400 NMR, CD<sub>2</sub>Cl<sub>2</sub>, 298 K):  $\delta$   $-152.5$  ppm (s, BF<sub>4</sub>). Anal. calcd. for C<sub>48</sub>H<sub>60</sub>BF<sub>4</sub>IrN<sub>4</sub>P (1003.42 + CH<sub>2</sub>Cl<sub>2</sub>): C, 54.10; H, 5.74; N, 5.15%. Found: C, 54.89; H, 6.08; N, 5.62%.

### General procedure for the catalytic silylation of C–H bonds

A sealed flask was charged with complex **1** (5 mol%), THF (2.0 mL), an arene (1 eq., 0.13 mmol), norbornene (3 eq., 0.40 mmol) and a hydrosilane (3 eq., 0.40 mmol). The solution was kept at 110 °C in a thermostatic bath for the reaction time described in the article. The progress of the reactions was monitored by <sup>1</sup>H NMR spectroscopy and the conversion was determined by integration of the peaks of the starting material with the peaks of the products. At the end of the reaction, the solution was concentrated under reduced pressure to afford the crude residue, which was purified by column chromatography on silica gel using mixtures of hexane/ethyl acetate to isolate the corresponding product.

## Acknowledgements

This work was supported by the Spanish Ministry of Economy and Competitiveness (MINECO/FEDER) (CONSOLIDER INGENIO CSD-2009-00050, CTQ-2015-67366-P and CTQ-2013-42532-P projects) and the DGA/FSE-E07. The support from the KFUPM-University of Zaragoza research agreement and the Centre of Research Excellence in Petroleum Refining & KFUPM is gratefully acknowledged. V. P. thankfully acknowledges the resources from the supercomputer "Memento", technical expertise and assistance provided by BIFI-ZCAM (Universidad de Zaragoza). L. R. -P. thanks CONACyT for a postdoctoral fellowship (204033). J. M. acknowledges financial support from the Ministry of Education Culture and Sports (FPU14/06003).

## Notes and references

‡ In the NMR characterisation, the terms py-a and py-b refer to the pyridine ligands *cis* and *trans* to the IPr ligand, respectively.

- (a) B. Marciniec, C. Pietraszuk, I. Kownacki and M. Zaidlewicz, in *Comprehensive Organic Functional Group Transformations*, ed. A. R. Katritzky and J. K. Taylor, Elsevier, Oxford, 2005, p. 941; (b) Y. Nakao and T. Hiyama, *Chem. Soc. Rev.*, 2011, **40**, 4893–4901; (c) I. Ojima, in *The Chemistry of Organic Silicon Compounds*, ed. S. Patai and Z.

- Rappoport, Wiley, New York, 1989, p. 1479; (d) I. Ojima, Z. Li, J. Zhu, in *The Chemistry of Organic Silicon Compounds*, ed. Z. Rappoport and Y. Apeloig, Wiley, New York, 1998, p. 1687; (e) G. W. Gribble and J. J. Li, in *Palladium in Heterocyclic Chemistry: a Guide for the Synthetic Chemist*, ed. G. W. Gribble and J. J. Li, Elsevier, Oxford, 2006, p. 12; (f) I. Fleming, J. Dunoguès and R. Smithers, in *Organic Reactions*, ed. A. S. Kende, Wiley, New York, 1989, vol. 2, pp. 57–193; (g) T.-Y. Luh and S.-T. Liu, in *The Chemistry of Organic Silicon Compounds*, ed. Y. A. Z. Rappoport, Wiley, Chichester, 2003, vol. 2, pp. 1793–1868.
- S. A. Ponomarenko and S. Kirchmeyer, in *Silicon Polymers*, ed. A. M. Muzafarov, Springer-Verlag, Heidelberg, 2010, pp. 36–110.
- For examples see: (a) R. J. Holmes, B. W. D'Andrade, S. R. Forrest, X. Ren, J. Li and M. E. Thompson, *Appl. Phys. Lett.*, 2003, **83**, 3818–3820; (b) X. Ren, J. Li, R. J. Holmes, P. I. Djurovich, S. R. Forrest and M. E. Thompson, *Chem. Mater.*, 2004, **16**, 4743–4747; (c) J.-K. Bin, N.-S. Cho and J.-I. Hong, *Adv. Mater.*, 2012, **24**, 2911–2915; (d) J.-J. Lin, W.-S. Liao, H.-J. Huang, F.-I. Wu and C.-H. Cheng, *Adv. Funct. Mater.*, 2008, **18**, 485–491; (e) M.-H. Tsai, H.-W. Lin, H.-C. Su, T.-H. Ke, C.-c. Wu, F.-C. Fang, Y.-L. Liao, K.-T. Wong and C.-I. Wu, *Adv. Mater.*, 2006, **18**, 1216–1220; (f) M.-K. Leung, W.-H. Yang, C.-N. Chuang, J.-H. Lee, C.-F. Lin, M.-K. Wei and Y.-H. Liu, *Org. Lett.*, 2012, **14**, 4986–4989; W.-S. Han, H.-J. Son, K.-R. Wee, K.-T. Min, S. Kwon, I.-H. Suh, S.-H. Choi, D. H. Jung and S. O. Kang, *J. Phys. Chem. C*, 2009, **113**, 19686–19693.
- (a) P. D. Lickiss, *Adv. Inorg. Chem.*, 1995, **42**, 147–262; (b) S. E. Denmark and L. Neuville, *Org. Lett.*, 2000, **2**, 3221–3224; (c) K. Hirabayashi, J.-i. Ando, J. Kawashima, Y. Nishihara, A. Mori and T. Hiyama, *Bull. Chem. Soc. Jpn.*, 2000, **73**, 1409–1417; (d) S. E. Denmark and D. Wehrli, *Org. Lett.*, 2000, **2**, 565–568.
- (a) M. Murata, M. Ishikura, M. Nagata, S. Watanabe and Y. Masuda, *Org. Lett.*, 2002, **4**, 1843–1845; (b) A. S. Manoso and P. DeShong, *J. Org. Chem.*, 2001, **66**, 7449–7455; (c) S. E. Denmark, R. C. Smith, W.-T. T. Chang and J. M. Muhuhi, *J. Am. Chem. Soc.*, 2009, **131**, 3104–3118; (d) S. E. Denmark and J. M. Kallemeyn, *J. Am. Chem. Soc.*, 2006, **128**, 15958–15959; (e) L. J. Gooßen and A.-R. S. Ferwanah, *Synlett*, 2000, **12**, 1801–1803.
- For examples of intramolecular silylation see: (a) E. M. Simmons and J. F. Hartwig, *J. Am. Chem. Soc.*, 2010, **132**, 17092–17095; (b) Q. Li, M. Driess and J. F. Hartwig, *Angew. Chem., Int. Ed.*, 2014, **53**, 8471–8474; (c) A. Kuznetsov and V. Gevorgyan, *Org. Lett.*, 2012, **14**, 914–917; (d) A. Kuznetsov, Y. Onishi, Y. Inamoto and V. Gevorgyan, *Org. Lett.*, 2013, **15**, 2498–2501.
- For examples of directed silylation with disilanes see: (a) M. Tobisu, Y. Ano and N. Chatani, *Chem.-Asian J.*, 2008, **3**, 1585–1591; (b) N. A. Williams, Y. Uchimaru and M. Tanaka, *J. Chem. Soc., Chem. Commun.*, 1995, 1129–1130; (c) K. S. Kanyiva, Y. Kuninobu and M. Kanai, *Org. Lett.*, 2014, **16**, 1968–1971.



- 8 For examples of directed silylation with hydrosilanes in the presence of a hydrogen acceptor see: (a) F. Kakiuchi, K. Igi, M. Matsumoto, N. Chatani and S. Murai, *Chem. Lett.*, 2001, **30**, 422–423; (b) F. Kakiuchi, K. Igi, M. Matsumoto, T. Hayamizu, N. Chatani and S. Murai, *Chem. Lett.*, 2002, **31**, 396–397; (c) H. Ihara and M. Suginoe, *J. Am. Chem. Soc.*, 2009, **131**, 7502–7510; (d) J. Oyamada, M. Nishiura and Z. Hou, *Angew. Chem., Int. Ed.*, 2011, **50**, 10720–17023.
- 9 For examples of acceptor-less directed silylation see: T. Sakurai, Y. Matsuoka, T. Hanataka, N. Fukuyama, T. Namikoshi, S. Watanabe and M. Murata, *Chem. Lett.*, 2012, **41**, 374–376.
- 10 (a) Y. Ma, B. Wang, L. Zhang and Z. Hou, *J. Am. Chem. Soc.*, 2016, **138**, 3663–3666; (b) A. A. Toutov, W.-B. Liu, K. N. Betz, A. Fedorov, B. M. Stoltz and R. H. Grubbs, *Nature*, 2015, **518**, 80–84.
- 11 (a) K. Ezbiansky, P. I. Djurovich, M. LaForest, D. J. Sinning, R. Zayes and D. H. Berry, *Organometallics*, 1998, **17**, 1455–1457; (b) W. A. Gustavson, P. S. Epstein and M. D. Curtis, *Organometallics*, 1982, **1**, 884–885.
- 12 (a) C. Cheng and J. F. Hartwig, *Chem. Rev.*, 2015, **115**, 8946–8975; (b) Y. Yang and C. Wang, *Sci. China: Chem.*, 2015, **58**, 1266–1279; (c) K. Takada, T. Hanataka, T. Namikoshi, S. Watanabe and M. Murata, *Adv. Synth. Catal.*, 2015, **357**, 2229–2232; (d) Y.-J. Liu, Y.-H. Liu, Z.-Z. Zhang, S.-Y. Yan, K. Chen and B.-F. Shi, *Angew. Chem., Int. Ed.*, 2016, **55**, 13859–13862; (e) W. Li, X. Huang and J. You, *Org. Lett.*, 2016, **18**, 666–668.
- 13 For the preparation of silatranes by C–H bond silylation see: T. Ishiyama, T. Saiki, E. Kishida, I. Sasaki, H. Ito and N. Miyaura, *Org. Biomol. Chem.*, 2013, **11**, 8162–8165.
- 14 For applications of trialkoxysilanes in cross-coupling see: (a) P. Y. S. Lam, S. Deudon, K. M. Averill, R. Li, M. Y. He, P. DeShong and C. G. Clark, *J. Am. Chem. Soc.*, 2000, **122**, 7600–7601; (b) P. Tang and T. Ritter, *Tetrahedron*, 2011, **67**, 4449–4454; (c) S. Riggleman and P. DeShong, *J. Org. Chem.*, 2003, **68**, 8106–8109.
- 15 For applications of trialkoxysilanes in fluorination and oxidation reactions see: (a) T. Furuya and T. Ritter, *Org. Lett.*, 2009, **11**, 2860–2863; (b) K. Tamao, N. Ishida, T. Tanaka and M. Kumada, *Organometallics*, 1983, **2**, 1694–1696; (c) K. Tamao, N. Ishida and M. Kumada, *J. Org. Chem.*, 1983, **48**, 2120–2122; (d) A. Hosomi, S. Iijima and H. Sakurai, *Chem. Lett.*, 1981, **10**, 243–246.
- 16 (a) Y. Uchimarui, A. M. M. E. Sayed and M. Tanaka, *Organometallics*, 1993, **12**, 2065–2069; (b) M. Koyanagi, N. Eichenauer, H. Ihara, T. Yamamoto and M. Suginoe, *Chem. Lett.*, 2013, **42**, 541–543; (c) J. Oyamaga, M. Nishiura and Z. Hou, *Angew. Chem., Int. Ed.*, 2011, **50**, 10720–10723; (d) Y. Sunada, H. Soejima and H. Nagashima, *Organometallics*, 2014, **33**, 5936–5939.
- 17 For precedents of C–H silylation by triarylsilanes see: (a) F. Kakiuchi, K. Tsuchiya, M. Matsumoto, E. Mizushima and N. Chatani, *J. Am. Chem. Soc.*, 2004, **126**, 12792–12793; (b) D. Leifert and A. Studer, *Org. Lett.*, 2015, **17**, 386–389.
- 18 (a) C. Cheng and J. F. Hartwig, *Science*, 2014, **343**, 853–857; (b) C. Cheng and J. F. Hartwig, *J. Am. Chem. Soc.*, 2015, **137**, 592–595; (c) B. Lu and J. R. Falck, *Angew. Chem., Int. Ed.*, 2008, **47**, 7508–7510.
- 19 (a) K. Manna, T. Zhang, F. X. Greene and W. Lin, *J. Am. Chem. Soc.*, 2015, **137**, 2665–2673; (b) G. Choi, H. Tsurugi and K. Mashima, *J. Am. Chem. Soc.*, 2013, **135**, 13149–13161; (c) H. F. T. Klare, M. Oestreich, J.-i. Ito, H. Nishiyama, Y. Ohki and K. Tatsumi, *J. Am. Chem. Soc.*, 2011, **133**, 3312–3315; (d) M. Koyanagi, N. Eichenauer, H. Ihara, T. Yamamoto and M. Suginoe, *Chem. Lett.*, 2013, **42**, 541–543; (e) H. Fang, L. Guo, Y. Zhang, W. Yao and Z. Huang, *Org. Lett.*, 2016, **18**, 5624–5627.
- 20 (a) S. P. Nolan, *N-Heterocyclic Carbenes in Synthesis*, Wiley-VCH, Weinheim, 2006; (b) F. E. Hahn and M. C. Jahnke, *Angew. Chem., Int. Ed.*, 2008, **47**, 3122–3172; (c) L. A. Adrio and K. K. Hii, in *Organometallic Chemistry*, ed. I. J. S. Fairlamb and J. M. Lynam, RSC Publishing, London, 2009, vol. 35, pp. 62–92; (d) C. S. J. Cazin, in *Catalysis by Metal Complexes*, ed. C. Bianchini, D. J. Cole-Hamilton and P. W. N. M. van Leeuwen, Springer Science+Business Media, New York, 2011, vol. 32; (e) M. L. Clarke and J. J. R. Frew, in *Organometallic Chemistry*, ed. I. J. S. Fairlamb and J. M. Lynam, RSC Publishing, London, 2009, vol. 35, pp. 19–46; (f) A. Poulain, M. Iglesias and M. Albrecht, *Curr. Org. Chem.*, 2011, **15**, 3325–3336.
- 21 C. Cheng and J. F. Hartwig, *J. Am. Chem. Soc.*, 2014, **136**, 12064–12072.
- 22 (a) M. Albrecht, *Chem. Rev.*, 2010, **110**, 576–623; (b) K. R. Jain, W. A. Herrmann and F. E. Kühn, *Curr. Org. Chem.*, 2008, **12**, 1468–1478; (c) L. Rubio-Pérez, M. Iglesias, R. Castarlenas, V. Polo, J. J. Pérez-Torrente and L. A. Oro, *ChemCatChem*, 2014, **6**, 3192–3199.
- 23 (a) A. Di Giuseppe, R. Castarlenas, J. J. Pérez-Torrente, M. Crucianelli, V. Polo, R. Sancho, F. J. Lahoz and L. A. Oro, *J. Am. Chem. Soc.*, 2012, **134**, 8171–8183; (b) L. Rubio-Pérez, E. A. Jaseer, N. García, V. Polo, M. Iglesias and L. A. Oro, *Organometallics*, 2016, **35**, 569–578.
- 24 M. A. Esteruelas and L. A. Oro, *Chem. Rev.*, 1998, **98**, 577–588.
- 25 For the preparation of related complexes see: (a) M. J. Cowley, R. W. Adams, K. D. Atkinson, M. C. R. Cockett, S. B. Duckett, G. G. R. Green, J. A. B. Lohman, R. Kerssebaum, D. Kilgour and R. E. Mewis, *J. Am. Chem. Soc.*, 2011, **133**, 6134–6137; (b) B. J. A. van Weerdenburg, N. Eshuis, M. Tessari, F. P. J. T. Rutjes and M. C. Feiters, *Dalton Trans.*, 2015, **44**, 15387–15390; (c) B. J. A. van Weerdenburg, S. Glöggler, N. Eshuis, A. H. J. (Ton) Engwerda, J. M. M. Smits, R. de Gelder, S. Appelt, S. S. Wymenga, M. Tessari, M. C. Feiters, B. Blümich and F. P. J. T. Rutjes, *Chem. Commun.*, 2013, **49**, 7388–7390; (d) L. S. Lloyd, A. Asghar, M. J. Burns, A. Charlton, S. Coombes, M. J. Cowley, G. J. Dear, S. B. Duckett, G. R. Genov, G. G. R. Green, L. A. R. Highton, A. J. J. Hooper, M. Khan, I. G. Khazal, R. J. Lewis, R. E. Mewis, A. D. Roberts and A. J. Ruddlesden, *Catal. Sci. Technol.*, 2014, **4**, 3544–3554; (e) O. Torres, M. Martín and E. Sola, *Organometallics*, 2009, **28**, 863–870; (f) L. Rubio-Pérez, M. Iglesias, J. Munárriz,



- V. Polo, P. J. Sanz Miguel, J. J. Pérez-Torrentea and L. A. Oro, *Chem. Commun.*, 2015, **51**, 9860–9863.
- 26 S. Wubbolt and M. Oestreich, *Angew. Chem., Int. Ed.*, 2015, **54**, 15876–15879.
- 27 (a) M. Yoshida, S. Tsuzuki, M. Goto and F. Nakanishi, *J. Chem. Soc., Dalton Trans.*, 2001, 1498–1505; (b) A. Naka, Y. Matsumoto, T. Itano, K. Hasegawa, T. Shimamura, J. Ohshita, A. Kunai, T. Takeuchi and M. Ishikawa, *J. Organomet. Chem.*, 2009, **694**, 346–352.
- 28 (a) M.-k. Leung, W.-H. Yang, C.-N. Chuang, J.-H. Lee, C.-F. Lin, M.-K. Wei and Y.-H. Liu, *Eur. J. Org. Chem.*, 2008, 1161–1163; (b) M. Murata, H. Yamasaki, K. Uogishi, S. Watanabe and Y. Masuda, *Synthesis*, 2007, 2944–2946; (c) Y. Yamanoi, T. Taira, J. Sato, I. Nakamura and H. Hishihara, *Org. Lett.*, 2007, **9**, 4543–4546; (d) M. Murata, K. Oka, H. Yamasaki, S. Watanabe and Y. Masuda, *Synlett*, 2007, 1387–1390; (e) M. Murata, H. Yamasaki, T. Ueta, M. Nagata, M. Ishikura, S. Watanabe and Y. Masuda, *Tetrahedron*, 2007, **63**, 4087–4094; (f) M. Murata, H. Ohara, R. Oiwa, S. Watanabe and Y. Masuda, *Synthesis*, 2006, 1771–1774; (g) A. Hamze, O. Provot, M. Alami and J.-D. Brion, *Org. Lett.*, 2006, **8**, 931–934; (h) D. Karchtedt, A. T. Bell and T. D. Tilley, *Organometallics*, 2006, **25**, 4471–4482; (i) Y. Yamanoi, *J. Org. Chem.*, 2005, **70**, 9607–9609; (j) S. E. Denmark and J. M. Kallemeyn, *Org. Lett.*, 2003, **5**, 3483–3486; (k) W. Gu, S. Liu and R. B. Silverman, *Org. Lett.*, 2002, **4**, 4171–4174; (l) A. S. Manoso and P. J. DeShong, *J. Org. Chem.*, 2001, **66**, 7449–7455; (m) M. Murata, K. Suzuki, S. Watanabe and Y. Masuda, *J. Org. Chem.*, 1997, **62**, 8569–8571.
- 29 K. Kon, H. Suzuki, K. Takada, Y. Kohari, T. Namikoshi, S. Watanabe and M. Murata, *ChemCatChem*, 2016, **8**, 2202–2205.
- 30 T. Matsubara, N. Koga, D. G. Musaev and K. Morokuma, *J. Am. Chem. Soc.*, 1998, **120**, 12692–12693.
- 31 S. Kozuch and S. Shaik, *Acc. Chem. Res.*, 2011, **44**, 101–110.
- 32 (a) L. Rubio-Pérez, M. Iglesias, R. Castarlenas, V. Polo, J. J. Pérez-Torrente and L. A. Oro, *ChemCatChem*, 2014, **6**, 3192–3199; (b) F. Maseras, A. Lledós, E. Clot and O. Eisenstein, *Chem. Rev.*, 2000, **100**, 601–636.
- 33 F. J. McQuillin and M. S. Baird, in *Alicyclic Chemistry, Cambridge Texts in Chemistry and Biochemistry*, Cambridge University Press, Cambridge, 2nd edn, 1983.
- 34 (a) J. A. M. Lummiss, C. S. Higman, D. L. Fyson, R. McDonald and D. E. Fogg, *Chem. Sci.*, 2015, **6**, 6739–6746; (b) M. S. Sanford, J. A. Love and R. H. Grubbs, *J. Am. Chem. Soc.*, 2001, **123**, 6543–6554.

